Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 70%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Guardant Health, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +44% YoY in Q2 FY2026.
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 21d ago
GH's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on GH.
Free accounts see more of this; Premium sees all of it.
Reported figures for Guardant Health, Inc. — research only, not investment advice.
Updated
What happened recently for Guardant Health, Inc. (GH) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
GH's AI investment thesis
Upgrade to Premium for GH's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$177.25
Market cap
$23.79B
Profitable
No
Revenue $335.00M
Net income
$-120.10M
FY Sep 27, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Guardant Health, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Guardant Health, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
Gene editing and mRNA platforms are moving from research curiosity to approved therapies faster than the market expected.
Surgical robots, mRNA pipelines, and liquid biopsies are converging—and most investors are still treating them as separate bets.
Breakthroughs in gene editing and targeted therapies are reshaping healthcare landscapes.
Breakthroughs in therapies, diagnostics, and digital health are transforming medical outcomes.